THX Pharma
ALTHX.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.12 | 0.00 | -0.16 | 0.02 |
| FCF Yield | 0.00% | -11.05% | -35.01% | -29.61% |
| EV / EBITDA | 0.00 | -6.03 | -50.72 | -3.04 |
| Quality | ||||
| ROIC | 0.00% | -155.49% | 4.08% | -54.39% |
| Gross Margin | 0.00% | -1,851.73% | 43.57% | -3,472.77% |
| Cash Conversion Ratio | 0.58 | -22.62 | 0.80 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 96.46% | 44.07% | 41.72% | 2.84% |
| Free Cash Flow Growth | 0.00% | 76.12% | 10.50% | 34.40% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -1.83 | -14.14 | -0.67 |
| Interest Coverage | 0.00 | -19.83 | -6.78 | -96.98 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 1,379.61 | -78.65 | -32.26 |